IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,32 -0,71 (-0,86%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
59.560,59 +4.641,94 (+8,45%)
TRACON Pharmaceuticals, Inc. (TCON)
Después del cierre:
TRACON Pharmaceuticals, Inc.
4350 La Jolla Village Drive
Suite 800
San Diego, CA 92122
United States
858 550 0780
https://www.traconpharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 17
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Charles P. Theuer M.D., Ph.D. | Chairman, CEO & President | 646,6k | N/A | 1964 |
| Mr. Scott B. Brown CPA, M.S. | Chief Financial Officer | 403,1k | N/A | 1981 |
| Dr. James L. Freddo M.D. | Chief Medical Officer | N/A | N/A | 1955 |
| Mr. Ya Huang | Executive Director of Statistical Programming | N/A | N/A | N/A |
Descripción
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Gobierno corporativo
El ISS Governance QualityScore de TRACON Pharmaceuticals, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
